EuroIntervention 2016;12:740-747 published online ahead of print October 2015. DOI: 10.4244/EIJY15M10_01
Aims: Among antirestenotic compounds, sirolimus displays a superior safety profile compared to paclitaxel, but its pharmacokinetic properties make it a challenging therapeutic candidate f
Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com